Chemotherapy-resistant urothelial carcinoma has no uniformly curative therapy.
Understanding how selective pressure from chemotherapy directs the evolution of urothelial …

The development of rapid genome sequencing has greatly enhanced our understanding of
the molecular biology underlying many malignancies. Whole exome sequencing has …

Background Three-quarters of bladder cancer patients present with early-stage disease
(non-muscle-invasive bladder cancer, NMIBC, UICC TNM stages Ta, T1 and Tis); however …

In this issue of Cancer Cell, Hedegaard et al. report a comprehensive multi-center
transcriptional analysis of non-muscle invasive urothelial bladder cancer. They describe …

Aims The advent of immune checkpoint inhibitor therapy has proven beneficial in a subset of
high-grade urothelial carcinomas (HGUC) of the bladder. Although treatment selection is …

The Cancer Genome Atlas (TCGA) project in bladder cancer reported the integrated
genomic analysis of the first 131 patients in 2014 [1]. We analyzed chemotherapy-naive …

This Platinum Opinion article summarizes the bladder Keynote Lecture presented during
ASCO-GU 2015 in Orlando. Systemic therapy for advanced urothelial carcinoma (UC) has …

Background Muscle-invasive bladder cancers (MIBCs) cause approximately 150 000 deaths
per year worldwide. Survival for MIBC patients is heterogeneous, with no clinically validated …

Purpose: Upper tract urothelial carcinoma is rare and less well studied than bladder cancer.
It remains questionable if findings in bladder cancer can safely be extrapolated to upper tract …

Prognoses for patients with metastatic urothelial carcinoma (mUC) have improved with
pembrolizumab treatment, an immune checkpoint inhibitor, but clinical benefits are limited to …